General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

Slides:

Advertisements

Similar presentations

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.

Advertisements

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.

Importance of Pharmacogenetics in Oncology Richard Pazdur, MD. Director Office of Oncology Drug Products Center for Drug Evaluation and Research Food and.

Special Topics in IND Regulation

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

Medical Devices Approval Process

Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals

Principles of New Animal Drug Effectiveness: An Overview

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,

Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.

Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.

Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Specific Clinical/Regulatory Issues in Development of Drugs for Peripheral Neuropathy and Neuropathic Pain Gerald J. Dal Pan, MD, MHS Medical Officer Division.

Dietary Supplements Bradford W. Williams Special Assistant Division of Dietary Supplement Programs ONPLDS, CFSAN, FDA.

Regulatory Overview.

1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

Overview of the Clinical Trial & Protocol Jane Fendl March 31, 2010

Center for Drug Evaluation and Research August 2005 Electroretinography: The FDA’s Viewpoint Wiley A. Chambers, MD Deputy Director Division of Anti-Infective.

Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,

Investigational New Drug Application (IND)

When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

Animal Models for Porcine Xenotransplantation Products Intended to Treat Type 1 Diabetes or Acute Liver Failure CTGTAC #47 May 14, 2009.

Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.

INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

1 PhRMA Guiding Principles - DTC About Prescription Medicines.

Risk Management in premarketing phase Anshu Vashishtha MD PhD (in individual capacity employer : Watson Pharmaceuticals)

UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.

Overview of FDA's Regulatory Framework for PET Drugs

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.

History of Pediatric Labeling

Substantial Evidence of Drug Effectiveness Cindy L. Burnsteel, DVM Division of Therapeutic Drugs for Food Animals Center for Veterinary Medicine March.

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.

Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.

CS-1 Regulatory Considerations: PDD Indication for Exelon ® (rivastigmine) Martina Struck, PhD Senior Associate Director Drug Regulatory Affairs Novartis.

Radiology Advisory Panel Meeting Radiology Advisory Panel Meeting Computer-Assisted Detection (CADe) Devices Joyce M. Whang Deputy Division Director Radiological.

Regulation of Generic Animal Drugs in the United States

1 IND Applications for Academic Clinical Investigations John Marler, MD US Food and Drug Administration New Hampshire Avenue White Oak, MD

Recent FDA Activities in Safe Use of Opioids Bob Rappaport, M.D. Director, Division of Anesthesia, Analgesia, and Addiction Products Center for Drug Evaluation.

Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,

GCP (GOOD CLINICAL PRACTISE)

Clinical Trials.

Responsibilities of Sponsor, Investigator and Monitor

Introduction to EPARs and FDA Approval Packages: Finding and Analyzing Unpublished Information about Pivotal Studies 23 June 2008 Session Chair: Amy N.

Drug Development Process Stages involved in Regulating Drugs

Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.

Division of Cardiovascular Devices

Responsibilities of Sponsor, Investigator and Monitor

Premarket Notification 510(k) process

FDA’s IDE Decisions and Communications

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Suzanne M. Sensabaugh, MS, MBA

Regulatory Perspective of the Use of EHRs in RCTs

Presentation transcript:

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products, FDA

Hypothesis: Drug A is capable of treating Symptom Complex Z in a safe and effective manner. Proof: At least two adequate and well-controlled trials demonstrating the hypothesis to be true, additional safety monitoring as needed. Results: Approval of Drug A with label. Promotion of Drug A based on findings of efficacy

What is the regulatory basis for studies used to support a finding of efficacy in an application? What is the regulatory basis for the requirements of the safety database? How are these findings, the product label, and product promotion related?

Efficacy Requirement for demonstration of efficacy based on amendments to the Food, Drug and Cosmetic Act, Section 505(a) of 21 U.S.C. 355 states that "No person shall introduce or delivery for introduction into interstate commerce any new drug, unless an approval of a an application filed pursuant to subsection (b) or (j) is effective with respect to such drug.”

Efficacy Section 505(b)(1)(A): “full reports of investigations which have been made to show whether or not such drug is safe for use and whether such drug is effective in use” shall be submitted as part of the application.

Efficacy Section 505(d)(5): a finding of “substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling…” is needed for approval of the application.

Efficacy The term “substantial evidence” is defined in 505(d) as “evidence consisting of adequate and well-controlled investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports …”

Efficacy 21 CFR The essential characteristics of an adequate and well-controlled trial, including the required documentation of planning, conduct, data handling and record keeping.

Efficacy “The Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products (May 1998)”.

Safety ICH E1A Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions

Label 21 CFR (c)(2) “All indications shall be supported by substantial evidence of effectiveness based on adequate and well-controlled studies as defined in § (b) of this chapter unless this requirement is waived under § or § (b) of this chapter.”

Label The Contraindications, Warnings, and Adverse Reactions Sections (d), (e), and (g) will be based initially on information from clinical trials and may have based on postmarketing reports.

Advertising Section 202.1(e)(3)(ii) “The information relating to effectiveness shall include specific indications for use of the drug for purposes claimed in the advertisement … for which the drug is effective clinically as specifically as required, approved, or permitted in the drug package labeling.”

Advertising 1. It is necessary to set a level playing field. 2. A product used for more than one indication may have different dosing requirements for those indications. 3. Different indications - different patient populations - different safety profiles. Age, co-morbidity, concomitant medications /potential drug-drug interactions. Safety data needed for fair balance.

Clinical Trials Efficacy Safety Product Label Product Advertising